September 14, 2012—Seventeen U.S. senators have asked the Centers for Medicare and Medicaid Services (CMS) to clarify that drug manufacturers can provide nominally priced pharmaceuticals to women’s health centers and family-planning clinics that do not participate in the 340B program without fear of lowering those products’ Medicaid best price.
The senators made their request in an Aug. 10 letter to CMS Acting Administrator Marilyn Tavenner.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)